Antirheumatic treatment is associated with reduced serum Syndecan-1 in Rheumatoid Arthritis

• DOI: 10.1371/journal.pone.0253247
• Publication Date: 2021-07-09T17:56:05Z
• Authors: Gia Deyab; Trine Marita Reine; Tram Thu Vuong; Trond Jenssen; Gunnbjørg Hjeltnes; Stefan Agewall; Knut Mikkelsen; Øystein Førre; Morten Wang Fager...; Svein Olav Kolset; Ivana Hollan
• Keywords: Syndecan 1

The endothelial glycocalyx (EG) is essential for proper function of the endothelium and vascular integrity, but its role in premature atherogenesis rheumatoid arthritis (RA) has not been studied yet. EG impairment can play a pathogenesis disease, one characteristics shedding syndecan-1 from cells. Syndecan-1 mediated by matrix metalloproteinase-9 (MMP-9) counteracted tissue inhibitor metalloproteinases (TIMP)-1. Cardiovascular disease risk RA reversible modifying antirheumatic drugs (DMARDs), exact modes action are still unclear. Therefore, we examined effects DMARDs on syndecan-1, MMP-9 TIMP-1 patients, searched associations between these parameters inflammatory activity. From observational PSARA study, 39 patients starting with methotrexate (MTX) monotherapy (in MTX naïve n = 19) or tumor necrosis factor inhibitors (TNFi) combination non-responders, 20) due to active RA. Serum were measured at baseline after six weeks treatment. (p 0.008) (p<0.001) levels decreased anti-rheumatic Levels also decreased, difference was statistically significant. improvement independent changes There no significant 6 TNFi groups, however change within group. Six treatment associated reduction serum which might reflect reduced EG. Thus, it possible that EG-preserving properties contribute their cardioprotective effects. These may be least partly anti-inflammatory actions. Our findings do support notion mainly increased TIMP-9 concentration.